Conference Coverage

Collaborative effort reduces COPD readmissions, costs


 

FROM ATS 2021

Revisits reduced

At the end of the program, 83% of participating sites had reductions in either ED visits or readmissions, and of this group, five sites had decreases in both measures.

Among all sites with improved metrics, the average rate of COPD-related ED revisits declined from 12.7% to 9%, and average inpatient readmissions declined from 20.1% to 15.6%.

As noted, the estimated cost savings in ED revisits avoided was $351,00, and the estimated savings in hospital readmission costs was $2.6 million.

“Although the centers didn’t have to participate in both parts, we did see in our results that the programs that participated fully had better results,” Dr. Press said.

“Historically, we’ve had such difficulty in decreasing COPD readmissions, and it’s nice to see something that actually works, both for patients and for conserving health resources,” Dr. Myers commented.

The study was supported by Vizient. Dr. Press disclosed honoraria from the company in her role as subject matter expert. Dr. Myers reported no conflicts of interest.

Pages

Recommended Reading

Cannabinoids may pose death risk for older patients with COPD
MDedge Internal Medicine
Clinically important deterioration predicts poor future outcomes in COPD
MDedge Internal Medicine
New guidelines on antibiotic prescribing focus on shorter courses
MDedge Internal Medicine
List of COVID-19 high-risk comorbidities expanded
MDedge Internal Medicine
Short-term oxygen prescriptions lead to inappropriate long-term use
MDedge Internal Medicine
Carbon monoxide diffusion with COPD declines more in women
MDedge Internal Medicine
Worse outcomes for patients with COPD and COVID-19
MDedge Internal Medicine
Sex differences in COPD symptoms predict cardiac comorbidity
MDedge Internal Medicine
Patients with moderate COPD also benefit from triple therapy
MDedge Internal Medicine
COPD in younger adults deadlier than expected
MDedge Internal Medicine